Amgen pulls high-price version of Repatha in bid to raise sales

AMGEN said it is pulling the higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug. The drug is manufactured n Rhode Island. / BLOOMBERG NEWS FILE PHOTO
AMGEN said it is pulling the higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug. The drug is manufactured n Rhode Island. / BLOOMBERG NEWS FILE PHOTO
NEW YORK – Amgen Inc. will pull its higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug by offering only a lower-priced version of the product. The move locks in a price cut Amgen announced last year. Effective Dec. 31, the remaining version of the heart…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display